Patents by Inventor Leila Mekkaoui
Leila Mekkaoui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11814641Abstract: The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and/or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and/or the cytokine-based T-cell activating transmembrane protein.Type: GrantFiled: March 4, 2021Date of Patent: November 14, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Leila Mekkaoui
-
Publication number: 20230293647Abstract: The present invention provides polypeptides with coronavirus neutralising capacity.Type: ApplicationFiled: April 9, 2021Publication date: September 21, 2023Inventors: Mathieu Ferrari, Shimobi Onuoha, Martin Pulé, Alexander Kinna, Leila Mekkaoui, Preeta Datta
-
Publication number: 20230220077Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.Type: ApplicationFiled: January 12, 2023Publication date: July 13, 2023Inventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
-
Patent number: 11578126Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.Type: GrantFiled: September 17, 2019Date of Patent: February 14, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
-
Publication number: 20210348191Abstract: The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and/or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and/or the cytokine-based T-cell activating transmembrane protein.Type: ApplicationFiled: March 4, 2021Publication date: November 11, 2021Inventors: Martin Pulé, Leila Mekkaoui
-
Patent number: 10954530Abstract: The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and/or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and/or the cytokine-based T-cell activating transmembrane protein.Type: GrantFiled: March 1, 2016Date of Patent: March 23, 2021Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Leila Mekkaoui
-
Patent number: 10745715Abstract: The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and iii) a membrane targeting domain such that, when incorporated a retroviral vector, the tagging protein facilitates purification of the retroviral vector from cellular supernatant via binding of the tagging protein to the capture moiety. The present invention also relates to a retroviral vector comprising such a producer cell-derived tagging protein.Type: GrantFiled: August 28, 2015Date of Patent: August 18, 2020Assignee: UCL BUSINESS LTDInventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung
-
Patent number: 10704032Abstract: The present invention relates to a retrovirus packaging cell which expresses a temperature sensitive RNA-dependent-RNA polymerase (RdRp).Type: GrantFiled: February 24, 2017Date of Patent: July 7, 2020Assignee: UCL BUSINESS LTDInventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung
-
Publication number: 20200140544Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.Type: ApplicationFiled: September 17, 2019Publication date: May 7, 2020Inventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
-
Patent number: 10457730Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.Type: GrantFiled: March 4, 2016Date of Patent: October 29, 2019Assignee: UCL BUSINESS PLCInventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
-
Publication number: 20190055568Abstract: The present invention relates to a nucleic acid construct comprising: (i) a first nucleic acid sequence which either comprises a retroviral transfer vector or which encodes a retroviral protein; and (ii) a second nucleic acid sequence which encodes a detectable marker which is a cell surface protein comprising an extracellular domain and a membrane targeting domain.Type: ApplicationFiled: February 24, 2017Publication date: February 21, 2019Inventors: Martin Pulé, Leila Mekkaoui
-
Publication number: 20190055526Abstract: The present invention relates to a retrovirus packaging cell which expresses a temperature sensitive RNA-dependent-RNA polymerase (RdRp).Type: ApplicationFiled: February 24, 2017Publication date: February 21, 2019Inventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung
-
Publication number: 20180066280Abstract: The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and/or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and/or the cytokine-based T-cell activating transmembrane protein.Type: ApplicationFiled: March 1, 2016Publication date: March 8, 2018Inventors: Martin Pulé, Leila Mekkaoui
-
Publication number: 20180044417Abstract: There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1-GY-AFSSS (SEQ ID No. 1); CDR2-YPGDED (SEQ ID No. 2) CDR3-SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1-SASSSVSYMH (SEQ ID No. 4); CDR2-DTSKLAS (SEQ ID No. 5) CDR3-QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.Type: ApplicationFiled: March 4, 2016Publication date: February 15, 2018Inventors: Martin Pulé, Leila Mekkaoui, Persis Amrolia, Sara Ghorashian, Anne Kramer, Gordon Cheung
-
Publication number: 20170240920Abstract: The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and iii) a membrane targeting domain such that, when incorporated a retroviral vector, the tagging protein facilitates purification of the retroviral vector from cellular supernatant via binding of the tagging protein to the capture moiety. The present invention also relates to a retroviral vector comprising such a producer cell-derived tagging protein.Type: ApplicationFiled: August 28, 2015Publication date: August 24, 2017Inventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung